medigraphic.com

2005, Number S1

Arch Cardiol Mex 2005; 75 (S1)

RENASICA II Mexican Registry of Acute Coronary Syndromes

García-Castillo A, Jerjes-Sánchez C, Martínez Bermúdez P, Azpiri LJR, Autrey CA, Martínez SC, Ramos CMA, Llamas G, Martínez SJ, Treviño AJ

Language: Spanish
References: 30
Page: 6-19
PDF size: 112.44 Kb.


ABSTRACT

Objective: The registry intends to establish the clinical characteristics, identify therapeutic approaches and describe in-hospital outcome of patients with acute coronary syndromes in Mexico. Methods and results: RENASICA II is a prospective registry that included 8,098 patients with final diagnosis of acute coronary syndromes. Three thousand five hundred and forty three patients had unstable angina or non-ST elevation myocardial infarction (UA/NSTEMI) and 4,555 ST elevation myocardial infarction (STEMI). On admission typical chest pain was identified in 78% and 85% respectively. Non-ST elevation high risk group was identified in 36%. In STEMI group anterior myocardial infarction and Killip class I had higher occurrence. The use of aspirin, unfractionated heparin, low molecular weight heparin, nitrates, beta blockers and ACE inhibitors for patients with UA/NSTEMI were 90%, 50%, 45%, 58%, 50% and 54% respectively, with corresponding rates of 88%, 54%, 44%, 66%, 51% and 64% for STEMI patients. Coronary angiography, angioplasty and coronary bypass surgery were performed in 62%, 30% and 8% in UA/NSTEMI patients respectively with corresponding rates of 44%, 27% and 4% for STEMI group. Among patients with STEMI 37% were under fibrinolytic therapy and 15% received primary or facilitated angioplasty. Overall In-hospital mortality was 7%, 4% for UA/NSTEMI and 10% for STEMI. Conclusion: The largest registry on ACS in Latin-America provides important and reliable information on complete spectrum, outcome, quality of care, and identifies areas for further improvement of such quality. RENASICA II broadens our knowledge about how reperfusion and antithrombotic approaches modify the outcome and what needs to be improved in the real practice in Mexico.


REFERENCES

  1. Howson CP, Reddy KS, Ryan TJ, Bale JR, Editors; Committee on research, development and institutional strengthening for control of cardiovascular diseases in developing countries, Institute of medicine: Control of cardiovascular disease in developing countries: research, development and institutional strengthening. Washington, DC, national Academy Press, 1998.

  2. Chockaklingam A, Balaguer-Vintro, Achutti A, de Luna AB, Chalmers J, Farinaro E, et al: The World Heart Federation’s white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Can J Cardiol 2000; 16: 227-229.

  3. Fox KAA: An Introduction to the Global Registry of Acute Coronary Events: GRACE. Eur Heart J 2000; 2(Suppl F): F21-24.

  4. Guillot F, Moulard O: Projected populations of people aged over 50 years, and estimated prevalence of myocardial infarction and ischemic stroke cumulated in 14 countries: Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK, USA. Circulation 1998; 98(Suppl 1): A1421.

  5. Secretaría de Salud. Comunicado de prensa No. 206, 12/Septiembre/2004; http://www.salud. gob.mx/ssa_app/noticias/datos/2004-09-12-991.html

  6. Sistema Nacional de Información para la Salud (SINAIS). Principales causas de mortalidad general, 2002 nacional; http//www.salud.gob.mx/apps/ htdocs/estadisticas/mortalidad/mortalidad. html

  7. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.

  8. Hamm CW, Bertrand M, Braunwald E: Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001; 358: 1533-1538.

  9. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden, et al: Management of acute coronary syndrome in patients presenting without persistent ST- segment elevation. Eur Heart J 2002; 23: 1809-1840.

  10. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al: ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002. Circulation 2002; 106: 1893-1900.

  11. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al: Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.

  12. Por el Grupo Cooperativo RENASICA. El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA). Sociedad Mexicana de Cardiología. Arch Cardiol Mex 2002; 72: S45-S64.

  13. Alpert JS: Are data from clinical registries of any value? Eur Heart J 2000; 21: 1309-1401.

  14. Fox KAA. Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O: Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23:1177-1189.

  15. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. (Euro Heart Survey of ACS). Eur Heart J 2002; 23: 1190-1201.

  16. Fox KAA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G, on belhaf of the ENACT (European Network for acute coronary treatment investigators): The ENACT study: a pan-European survey of acute coronary syndromes. Eur Heart J 2000; 21: 1440-1449.

  17. Wu AH, Parsons L, Every NR, Bates E: Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40: 1389-1394.

  18. 1994 National Hospital Discharge Survey. Washington, DC; U.S. National Center for Health Statistics, 1995.

  19. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein W: Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999; 33: 107-108.

  20. Liebson PR, Klein LW: The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39: 399-444.

  21. Furman MI, Dauerman HL, Goldberg RJ, Yarsbeski J, Lessard D, Gore JM: Twenty-two year (1975 to 1977) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: A multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37: 1571-1581.

  22. Zeymer U, Senges J: Why do we need prospective registries in patients with acute myocardial infarction? Eur Heart J 2003; 24: 1611-1612.

  23. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrum AJ, Kinkaid B, Shoultz DA, et al: Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S from 1990 through 1999. The National Registry of Myocardial Infarction 1, 2, 3. J Am Coll Cardiol 2000; 36: 2056-263.

  24. Bartnika M, Rydén L, Ferraric R, Malmberga K, Pyörälä K, Simoonse M, et al: on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-1890.

  25. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.

  26. Doukky R, Calvin JE: Risk stratification in patients with unstable angina and non-ST segment elevation myocardial infarction: Evidence-based review. J Invasive Cardiol 2002; 14: 215-220.

  27. Calvin JE, Klein LW, VadenBerg BJ: Risk stratification in unstable angina: prospective validation of the Braunwald classification. JAMA 1995; 273: 136-141.

  28. Simmons ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab in patients with acute coronary syndromes without early coronary revascularization. The GUSTO IV ACS randomized trial. Lancet 2001; 357: 1914-1915.

  29. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibitions: the GUSTO V randomized trial. Lancet 2001; 357: 1905-1914.

  30. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.




2020     |     www.medigraphic.com